In colorectal tumors, the G12 KRAS mutation detected in 2 out of 15 samples, is predictive for a lack of response to the EGFR inhibitors cetuximab and panitumumab, associated to primary resistance (RI). Here, KRAS is linked to colorectal neoplasm.